Financial Data and Key Metrics Changes - Net sales for Q4 2025 totaled $1.33 billion, reflecting a 7% decline in units and a 2% decline in price compared to the previous year [4][19] - Gross profits decreased by 10% to $217 million from $240 million in the prior year, primarily due to challenges in the Site Built and ProWood business units [19][27] - Adjusted EBITDA for the quarter was $124 million, an 8% decline from $135 million last year, influenced by the decline in gross profit [22] - Free cash flow for the year was strong at $451 million, down only 5% from 2024, allowing for significant shareholder returns [23][33] Business Line Data and Key Metrics Changes - Retail segment sales were $444 million, a 15% decline, with a 13% decrease in unit sales and a 2% decrease in prices [23] - ProWood experienced a 13% unit decrease, while Deckorators saw a 17% increase in sales, driven by strong demand for wood-plastic composite and SureStone products [24] - Packaging segment sales declined 1% to $370 million, with consistent customer demand but competitive pricing [25] - Construction segment sales fell 10% to $440 million, driven by a 5% decline in both selling prices and units, particularly in the Site-Built business [26] Market Data and Key Metrics Changes - The overall market environment in 2025 was challenging, with cyclical and competitive pricing pressures affecting key markets [4][6] - Demand for housing remained weak due to affordability issues and consumer sentiment, particularly impacting the Site-Built business [15][26] - The packaging business showed signs of stabilization, but pricing remained competitive due to market softness [14][25] Company Strategy and Development Direction - The company plans to use its strong balance sheet to pursue meaningful M&A opportunities while continuing to return capital to shareholders [6][9] - A focus on innovation and the introduction of higher-margin products is central to the company's strategy, with new product sales accounting for 7.6% of total sales [7][8] - The company aims to achieve a 12.5% EBITDA margin and 7%-10% unit sales growth, with a commitment to maintaining a conservative capital structure [17] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, anticipating market share gains and cost-saving initiatives to offset headwinds in new residential construction [35] - The company is entering 2026 in a stronger position, having made significant progress in cost reduction and operational efficiency [6][36] - Management highlighted the importance of maintaining a balanced approach to capital allocation, focusing on organic and inorganic growth opportunities [33][34] Other Important Information - The company executed share repurchases of $443 million, representing 7% of outstanding shares, and paid $82 million in dividends, with a 3% dividend increase announced for 2026 [5][34] - The company has $2.2 billion in liquidity, providing flexibility for future investments and M&A activities [9][33] Q&A Session Summary Question: Update on Deckorators and cost opportunities - Management expects $100 million increase in Deckorators sales in 2026, heavily weighted towards decking, with significant margin growth opportunities as new capacities come online [41][43] Question: SG&A and facility consolidation opportunities - The heavy lifting for cost reductions has been completed, but management continues to seek opportunities for further efficiency [45][46] Question: M&A pipeline and opportunities - The M&A pipeline is more active than in the past three years, with a focus on strategic priorities and outreach to potential targets [52][83] Question: Trends in the packaging business - Management sees early signs of stabilization in the packaging segment, particularly in Structural Packaging, but remains cautious about overall growth [66] Question: Expectations for Site-Built and pricing stabilization - The first half of 2026 is expected to be challenging for Site-Built, but management is optimistic about potential improvements in the back half of the year [76][98]

Financial Data and Key Metrics Changes - Group revenues for the first nine months of 2025 reached EUR 535.1 million, reflecting a 7% decline compared to the previous year [9][18] - DNPD revenues declined by 12% to EUR 391.9 million, while Just - Evotec Biologics revenues grew by 11% to EUR 143.2 million [10][19] - Adjusted group EBITDA was negative EUR 16.9 million, driven by weaker DNPD revenues and fixed cost base [21] - Year-to-date free cash flow improved by 14% compared to the same period last year [22] Business Line Data and Key Metrics Changes - DNPD business faced continued softness in the early drug discovery market, leading to a 12% revenue decline [10] - Just - Evotec Biologics business showed strong growth with revenues up 11% in the first nine months [19] - Non-Sandoz and non-DOD customer base grew by over 100% in the first nine months [14] Market Data and Key Metrics Changes - Venture capital funding for biotech remains unfavorable, impacting business development activities [10][15] - The early drug discovery market is still experiencing a temporary deprioritization, with funding levels below pre-pandemic levels [15] Company Strategy and Development Direction - The company is focused on better monetizing its technology leadership and has raised its cost reduction target to EUR 60 million for 2025 [12] - A transformational deal with Sandoz was signed, expected to unlock payments exceeding $650 million over the coming years [14][39] - The strategy includes pivoting towards an asset-light, higher-margin business model, leveraging technology partnerships [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the midterm outlook despite current market challenges, with a targeted revenue of EUR 760 million to EUR 800 million for 2025 [45] - The company remains cautious about the early drug discovery market recovery, indicating that visibility into 2026 is limited [68] Other Important Information - The company anticipates up to four molecules from its partnered asset pipeline to enter phase two clinical studies in 2026 [13] - The total milestone potential of the asset pipeline is over EUR 16 billion, with significant royalties expected [34] Q&A Session Summary Question: What were Sandoz revenues in the first nine months? - Sandoz revenues accounted for over 50% of the overall year-to-date revenues [50] Question: How much of the EUR 30-50 million EBITDA guide is from the Sandoz deal? - There is a license recognition element from Sandoz included in the initial consideration, but it is not being split out at this stage [53] Question: What is the expected growth trajectory from 2025 to 2028? - The midterm outlook suggests 8-12% revenue CAGR with stronger potential for EBITDA margins than initially planned [55] Question: What is the current state of the early drug development market? - There is still uncertainty in the market, with more cautious spending and slower decision-making observed [77] Question: Are there geographic variations in market performance? - The US market showed less dynamism earlier in the year, while the European market has been more active recently [81]